公司資料
RXDX 股價、新聞與催化劑
- 股票代碼:
- RXDX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股價為何變動
Current closing-price context is not available for RXDX.
公司概覽
業務概覽
Prometheus Biosciences was an immunology-focused biotechnology company centered on precision medicine for inflammatory bowel disease before being acquired by Merck. Its story was built around translating biomarker-driven biology into targeted treatments.
所在地與產業分類
Prometheus was headquartered in the United States and traded on NASDAQ before the acquisition. It sat in immunology and precision biotechnology.
商業模式特徵
The company’s value was driven by clinical readouts, biomarker strategy, and the potential to create a differentiated treatment path in inflammatory disease. Investors watched data quality, target validation, and the strategic interest in its platform.
生技產業定位
Prometheus was a premium precision-immunology biotech and one of the more compelling catalyst-driven names of its era. Since it has been acquired, it is now part of biotech M&A history rather than the live public-company universe.
未來催化劑
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。